2018-11-12T05:37:06-00:00 2017-12-31 KPMG LLP 1918 8th Avenue Suite 2900 Seattle WA 98101 990 2017-01-01 910653422 Benaroya Research Institute at Virginia Mason BENA 2063426500 1201 Ninth Avenue Seattle WA 981012795 Homer W Lane Jr Executive DirectorCFO 2018-11-12 true Sue Robison 2069134000 2018-11-12 204.147.223.1 2018-11-13 01:33:39 PS P 3BF9F3C1D5421FE41D537B7E0F61F32192DE8497 3BF9F3C1D5421FE41D537B7E0F61F32192DE8497 2017 2019-02-21 02:37:17Z Jane Buckner MD 1201 Ninth Avenue Seattle WA 98101 68019757 false X http://www.benaroyaresearch.org X 1956 WA To conduct and encourage high quality medical, surgical, and scientific research and research training in disease and problems of medical importance. 20 15 332 4 0 71346495 60243416 8553010 6781431 394767 456650 347680 347680 80641952 67829177 29786250 27587861 0 25664449 25600727 0 0 19506635 18423765 74957334 71612353 5684618 -3783176 91306270 90102675 44301004 44389195 47005266 45713480 X Advancing the science that will predict, prevent, reverse and cure diseases of the immune system, such as autoimmune disease, allergy and asthma. false false 32265013 23471602 Immune Tolerance Network Program. See Schedule O. 8738789 1714167 Translational Program. See Schedule O. 6862100 1293149 Diabetes Progra. See Schedule O. 12940377 1108943 6781431 60806279 true true false true false false false false false true true true false false false false true false false false true true false false false false false true false true true false false true false false false false false false false false false false false false true false false false false true 104 0 true 332 true false false false false false false false false false false X 20 15 false false false false true true true true true false false true true true true true true true true false WA X Homer W Lane Jr Executive DirectorC 2063426508 1201 Ninth Avenue Seattle WA 981012795 Jane Buckner MD Ex Officio, President 040.00 X X 314832 0 24936 Carla Greenbaum MD Director 040.00 X 224224 0 30384 Joyce Lammert MD PhD Director 001.00 050.00 X 0 486335 26476 John Corman MD Director 001.00 050.00 X 0 597283 72982 Gary Kaplan MD Director 001.00 054.00 X 0 1127597 68995 Tom Cohen Director 001.00 X 0 0 0 Rebecca Campbell Director 001.00 X 0 0 0 Margaret Morrow Director, Secretary 001.00 X X 0 0 0 Frank Dvorak PhD Director, Vice Chair 001.00 X X 0 0 0 Patricia Markey Director 001.00 X 0 0 0 David Williams Director, Treasurer 001.00 004.00 X X 0 0 0 W Michael Gallatin PhD Director 001.00 X 0 0 0 Jessica Muffett Director 001.00 X 0 0 0 Carla DewBerry Director, Chair 001.00 X X 0 0 0 Christopher Wilson MD Director 001.00 X 0 0 0 Nabil Istafanous Director 001.00 X 0 0 0 Ben Rieber Director 001.00 X 0 0 0 Jeffrey Wortley Director 001.00 X 0 0 0 Catherine Zimmerman Director 001.00 X 0 0 0 Diane St John MBA Director 001.00 X 0 0 0 Homer Lane Jr Executive Director, CFO 040.00 X 262308 0 33306 Gerald Nepom MD PhD Program Director, ITN 024.00 X 149222 0 27192 Willliam Kwok PhD Research Member 040.00 X 229415 0 27336 Steven Ziegler PhD Director of Academic Affairs 040.00 X 220724 0 21612 James Lord MD Research Member 040.00 X 199380 0 22110 Lynn Rose PhD Director Scientific Administration 040.00 X 186196 0 24930 Philip Bernstein Research Member 040.00 X 176076 0 24744 1962377 2211215 405003 51 false true false Finley & Cook PLLC 601 North Broadway Shawnee OK 74801 Consulting 153505 KPMG LLP 1918 Eight Ave Suite 2900 Seattle WA 98101 Auditing Consulting 119227 Riverbend Design Group LLC 414 Stewart St siote 215 Seattle WA 98101 Consulting 101100 3 1750000 51827654 6665762 60243416 Commercial Studies 621500 3568126 3568126 Collaborative Research Core Services 621500 3213305 3213305 6781431 456650 456650 538260 190580 347680 347680 347680 67829177 6781431 804330 26209077 26209077 0 1378784 1378784 0 959603 574149 385454 0 19546742 14426390 5120352 1578890 1131956 446934 2095924 1502634 593290 1419568 1017732 401836 0 96312 96312 96027 96027 0 0 2436749 1704004 732745 54855 54855 110613 20251 90362 1676142 747050 929092 0 2787256 2441621 345635 335384 274853 60531 0 133449 104615 28834 629819 547943 81876 0 3696872 2890809 806063 41004 41004 Supplies 3927286 3827326 99960 Other Purchased Services 332777 185691 147086 Patient Costs 1099995 1099995 Research Partipants Fees 436391 436219 172 532834 285180 247654 71612353 60806279 10806074 0 10525094 6125815 2288001 363312 12690871 13584865 1620548 1647502 349640 400177 72695299 45459789 29599133 27235510 5312100 12181585 28068298 27320900 852585 1243009 91306270 90102675 12436607 11146141 4142907 6511564 27721490 26731490 44301004 44389195 X 20816818 18078247 12225413 13575861 13963035 14059372 47005266 45713480 91306270 90102675 -3783176 2491390 X false true X true true true X Virginia Mason Medical Center Seattle WA 44973133 54174085 59709893 71346495 60243416 290447022 44973133 54174085 59709893 71346495 60243416 290447022 27492877 262954145 642011 707157 430555 933027 994910 3707660 6122655 6639555 7021290 8553010 6781431 35117941 329272623 0.79860 0.79920 X 0.00000 0.00000 Part II Section B Line 10 2017 Other Income of 6,781,431 is comprised of 3,568,126 of Clinical Research Program revenue, 2,855,288 of Collaborative Research Agreement projects, 318,733 of External Core Income, and 39,284 of miscellaneous income. X 175480 108767 284247 71612353 1586599944 71612353 1586884191 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 138835 154766 275782 284247 853630 250000 250000 250000 250000 1000000 1500000 119335 108173 163134 175480 566122 false false false false false false false false false false false II-A A Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. II-A A continued Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 II-A A continued Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. II-A A continued Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 133,386 Direct Lobbying Expenditures 48,767. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2017. II-A A continued Yakima Valley Memorial Hospital Association, EIN 91-0567263, 2811 Tieton Drive, Yakima, WA 98902. Non-electing member. 42,094 Grassroots Lobbying Expenditures 60,000 Direct Lobbying Expenditures. Excess Lobbying Expenditures 0. false false true true 756906 756906 49523385 26816398 22706987 196862 196862 21956200 18446529 3509671 261946 261946 27235510 Financial derivatives and other financial products Closely-held equity interests Interest in Net Assets of Virginia Mason Health System 27320900 27320900 Federal income taxes 70320567 2491390 2491390 67829177 67829177 71612353 71612353 71612353 true Europe Including Iceland and Greenland Conferences Medical Research 26129 South America Conferences Medical Research 3269 Middle East and North Africa Conferences Medical Research 2225 31623 31623 Europe Including Iceland and Greenland Medical Research 499590 Wire Transfer Europe Including Iceland and Greenland Medical Research 181386 Wire Transfer Europe Including Iceland and Greenland Medical Research 79284 Wire Transfer Europe Including Iceland and Greenland Medical Research 49145 Wire Transfer Europe Including Iceland and Greenland Medical Research 41251 Wire Transfer North America Medical Research 13630 Wire Transfer North America Medical Research 6650 Wire Transfer North America Medical Research 6127 Wire Transfer East Asia and the Pacific Medical Research 367258 Wire Transfer East Asia and the Pacific Medical Research 89180 Wire Transfer East Asia and the Pacific Medical Research 45283 Wire Transfer 11 false false false false false false Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. Part I Line 3f The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. Part II Line 1 The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. true Ann&Robert H Lurie Children's Hospital of Chicago 225 East Chicago Ave No 205 Chicago IL 606112991 362170833 501c3 19249 Medical Research Arkansas Children's Hospital Research Institute One Childrens Way Financial Service Little Rock AR 722023591 710694931 501c3 105254 Medical Research Asthma Inc 9725 3rd Ave NE Suite 500 Seattle WA 98115 237219813 501c3 150235 Medical Research Baylor Research Institute 3301 Live Oak Suite 501 Dallas TX 75204 751921898 501c3 20414 Medical Research Brigham And Women's Hospital Bank of America NA POBox 3887 Boston MA 022413887 042312909 501c3 250516 Medical Research Children's Hosp of Philadelphia PO Box 8550 Lockbox 1457 Philadelphia PA 191781457 231352166 501c3 51375 Medical Research Children's Mercy Hospital 2401 Gillham Road Kansas City MO 64101 440605373 501c3 53258 Medical Research City Of Hope Attn Monrovla 2562 1500 East Duarte Duarte CA 91010 953435919 501c3 505000 Medical Research Columbia University Trustees of PO Box 29789 General Post Office New York NY 100879789 135598093 501c3 127854 Medical Research Dana-Farber Cancer Institute Inc 450 Brookline Ave 431C Boston MA 02215 042263040 501c3 286815 Medical Research Denver Nephrologists PC 130 Rampart Way Suite 300B Denver CO 80230 840591433 47686 Medical Research Dermatology Research Assoc Inc 8930 S Sepulveda Blvd Ste 114 Los Angeles CA 90045 273947370 26878 Medical Research Duke University PO Box 602651 Accounts Receivable L Charlotte NC 282602651 560532129 501c3 1195537 Medical Research Emory University 1599 Clifton Road NE 4th floor Atlanta GA 30322 580566256 501c3 312990 Medical Research Feinstein Institute for Medical Research 350 Community Drive Manhasset NY 11030 112673595 501c3 54994 Medical Research Fred Hutchinson Cancer Research Center 1100 Fairview Ave N J6-330 PO Box 1 Seattle WA 981091024 237156071 501c3 222261 Medical Research Hospital for Special Surgery 535 East 70th Street New York NY 10021 131624135 501c3 22260 Medical Research Icahn School of Medicine at Mount Sinai One Gustave L Levy Place Box 3500 O New York NY 100296574 136171197 501c3 273257 Medical Research Indiana University 400 E 7th St Poplars Room 501 Bloomington IN 47405 356001673 501c3 101322 Medical Research JDRF 26 Broadway 14th Floor New York NY 10004 231907729 501c3 19208 Medical Research Johns Hopkins University Central Lockbox c/o B of A 12529 Co Chicago IL 60693 520595110 501c3 1001174 Medical Research Jonathan Corren MD Inc 10780 Santa Monica Blvd 280 Allergy Los Angeles CA 90025 462346264 299704 Medical Research Joslin Diabetes Center One Joslin Place Boston MA 022155306 042203836 501c3 99147 Medical Research La Jolla Institute for Allergy & Immunology 9420 Athena Circle La Jolla CA 92037 330328688 501c3 135000 Medical Research Massachusetts General Hospital 55 Fruit Street Research Management Boston MA 02114 042697983 501c3 5643320 Medical Research Medical University of South Carolina 19 Hagood Avenue Ste 604 MSC 808 Charleston SC 29425 576000722 South Carolina 123045 Medical Research National Jewish Health 1400 Jackson Street M213 Denver CO 80206 742044647 501c3 77378 Medical Research New York University-School of Medicine PO Box 415026 Bank of America Boston MA 022415026 135562308 501c3 75897 Medical Research Northwestern University 633 Clark Room G547 ATTN ASRSP Evanston IL 60208 362167817 501c3 422083 Medical Research Ohio State University Office of Sponsored Programs 1960 K Columbus OH 43210 316025986 501c3 35561 Medical Research Oklahoma Medical Research Foundation 825 NE 13th Street Okahoma City OK 73104 730580274 501c3 129123 Medical Research Polyclinic Madison Center 904 7th Ave 6th Floo Seattle WA 98104 910369070 43061 Medical Research Rockefeller University 1230 York Ave Financial Post Award New York NY 100656307 131624158 501c3 83601 Medical Research Rogosin Institute Inc The 505 East 70th Street 2nd Floor New York NY 100214872 133184198 501c3 19853 Medical Research Rutgers the State University of New Jersey Office of Research and Sponsored Pr New Brunswick NJ 089018559 226001086 501c3 504757 Medical Research Sanford Research 2301 E 60th St N Attn Clinical Rese Sioux Falls SD 57104 460450378 501c3 75875 Medical Research Seattle Childrens Hospital PO Box 24728 Seattle WA 981240728 910564748 501c3 678860 Medical Research St Jude Children's Research Hospital Inc PO Box 1000 Dept 949 Memphis TN 381480949 620646012 501c3 194776 Medical Research Stanford University PO Box 44253 San Francisco CA 941444253 941156365 501c3 784166 Medical Research State University of Iowa 118 S Clinton St - SCST Attn Grant Iowa city IA 52242 426004813 Iowa 36975 Medical Research Tulane University 1430 Tulane Ave Dermatology 8036 At New Orleans LA 70112 720423889 501c3 21530 Medical Research Univ of Minnesota Regents 450 McNamara Alumni Center 200 Oak Minneapolis MN 554552070 416007513 Minnesota 88640 Medical Research Univ of Texas SW Med Ctr Grants Management PO Box 841753 Dallas TX 752841753 756002868 Texas 100668 Medical Research University of Alabama at Birmingham 1720 2nd Ave South AB 990 Birmingham AL 35294 636005396 Alabama 27190 Medical Research University of California Los Angeles 11000 Kinross Ave Ste 211 Los Angeles CA 90095 956006143 501c3 98386 Medical Research University of California San Francisco Controllers Office Contract Grants San Francisco CA 941430897 946036493 501c3 7804108 Medical Research University of Chicago 5841 S Maryland AveMC 5030 Room O-2 Chicago IL 60637 362177139 501c3 156821 Medical Research University of Colorado-Denver PO Box 910238 Denver CO 802910238 846000555 501c3 824353 Medical Research University of Florida Board of Trustees PO Box 113001 Gainesville FL 32611 596002052 501c3 32127 Medical Research University of Maryland Baltimore Sponsored Projects Acctng 220 Arch Baltimore MD 212011508 526002033 Maryland 14555 Medical Research University of Miami 1320 S Dixie Highway Gable One Towe Coral Gables FL 331462926 590624458 501c3 24027 Medical Research University of Michigan Box 223131 Pittsburgh PA 152512131 386006309 501c3 49643 Medical Research University of Nebraska Medical Center 985045 Nebraska Medical Center Omaha NE 681985045 470049123 501c3 160108 Medical Research University of North Carolina at Chapel Hill PO Box 402420 Bank of America Lockb Atlanta GA 303842420 566001393 501c3 395036 Medical Research University of Oklahoma Health Sciences 865 Research Parkway URP865-450 Oklahoma City OK 731043609 731563627 Oklahoma 91505 Medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 171785541 231352685 501c3 227089 Medical Research University of Pittsburgh Research/Cost Accounting PO Box 371 Pittsburgh PA 152517220 250965591 501c3 377797 Medical Research University of Texas Southwestern Medical Center Lock Box 845477 Dallas TX 752845477 756002868 Texas 34372 Medical Research University of Utah Grants and Contract Accounting 201 Salt Lake City UT 84132 876000525 501c3 18175 Medical Research University of WA Grants 12455 Collections Drive Chicago IL 606930001 916001537 Washington 583438 Medical Research University of Wisconsin Madison Board of Regents 600 Highland AveF8/138 CSC Madison WI 53792 396006492 501c3 249654 Medical Research Vanderbilt University Department of Finance Dept 1236 PO Dallas TX 753121236 620476822 501c3 38632 Medical Research Vital Prospects Clinical Research Institute PC 7307 S Yale Ave Suite 200 Tulsa OK 74136 261814411 110900 Medical Research Yale University Grant and Contract Financial Admini New Haven CT 065081873 080648973 501c3 362716 Medical Research 59 5 Part I Line 2 Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. X true true false false false false false false false false false Jane Buckner MD Ex Officio, President 314832 24000 936 339768 Carla Greenbaum MD Director 224224 24000 6384 254608 Joyce Lammert MD PhD Director 467090 25 19220 14846 11630 512811 John Corman MD Director 578860 8 18415 51365 21617 670265 Gary Kaplan MD Director 1103978 285 23334 27255 41740 1196592 Homer Lane Jr Executive Director, CFO 262308 24000 9306 295614 Gerald Nepom MD PhD Program Director, ITN 149222 24000 3192 176414 Willliam Kwok PhD Research Member 228915 500 24000 3336 256751 Steven Ziegler PhD Director of Academic Affairs 220724 16824 4788 242336 James Lord MD Research Member 199380 17634 4476 221490 Lynn Rose PhD Director Scientific Administration 184196 2000 18901 6029 211126 Philip Bernstein Research Member 176076 24000 744 200820 Part I Line 3 Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. Part I Line 4b The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives participate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. A WA Econ Devel Fin Auth-2012 Series B 911493002 2012-06-01 10390000 See Part VI false true false B WA Econ Devel Fin Auth-Series 2016 911493002 2016-06-01 18631490 See Part VI false true false A 1645000 10390348 2550348 7840000 2013 true false true true B 645000 18631490 18631490 true false true true A false true false true true 0.01630 0.01630 false false true B false true false true true 0.01630 0.01630 false false true A false true false false false false true B false true false false false false true A true B true Part I Line A Column F Purposes to currently refund WEDFA Series 2006C bonds issued 11/15/2006, and to fund research facility improvements. Part I Line B Column F Purposes to currently refund WEDFA Series 2012A taxable bonds issued 06/01/2012. No tax-exempt private activity bonds are being refunded. Part III Line 3 Difference between Part I, column e and Part II, line 3 is investment earnings. Form 990, Part III, Line 1 Benaroya Research Institute at Virginia Mason BRI is a world-renowned medical research institute whose work has resulted in major advances in our understanding of autoimmune and immune-mediated diseases. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight and development support through the Virginia Mason Foundation. In 2017, BRI scientists led four international centers for autoimmune disease research and collaborated with colleagues all over the world. These researchers generated 76 scientific publications that were published in prestigious research journals, delivered 133 presentations at domestic and international research conferences and received many major grants. Nearly half of BRIs research faculty also serve as affiliate professors at the University of Washington and mentor postdoctoral fellows, graduate students and summer interns. Their leadership, expertise, collaboration, dedication and curiosity drive our pioneering discoveries. Information about the diseases that BRI studies One in 15 Americans suffers from one of the more than 80 known autoimmune diseases, and 25 of these people suffer from more than one of these interrelated diseases. Autoimmune diseases include type 1 diabetes, multiple sclerosis, Crohns disease and rheumatoid arthritis to name a few. Even more Americans, one out of every four, suffer from other immune-mediated diseases, allergy and asthma. These are all lifelong conditions, currently without a cure. Because these diseases are connected by common destructive pathways, research on one or two immune system diseases has far reaching implications for the whole spectrum of immune-mediated disease. As a world leader in scientific innovation, BRIs discoveries are having significant impact on people living with these diseases today - by improving the ability to predict disease risk, prevent onset of disease, decrease disease progression, make treatments safer and better - while striving to ultimately cure these diseases. Form 990, Part III, Line 4 One of the unique qualities of BRI is the close integration of three types of medical research - laboratory research, translational research and clinical research - to improve peoples lives. Our scientists can address both the basic science issues and clinical applications, which is the best way to design studies with the highest potential for success. For BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. 2017 advancements in immunology, translational research, clinical research and other areas are highlighted below. Form 990, Part III, Line 4a Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in three clinical areas asthma and allergic diseases autoimmune diseases and immune-mediated rejection of transplanted solid organs, tissues and cells. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2017 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2017 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 154 subawards in 2017 in support of 20 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted one supplemental funding request in 2017. This request was awarded, bringing in an additional 2.9M in funding to the ITN BRI. b Partnerships The ITN added one pharmaceutical partner providing partial support for a new clinical trial and continued its relationship with two other pharmaceutical partners for partial funding on two ongoing ITN studies. NIAID is the clinical sponsor on all three of these trials. 4 Publication Activity In 2017, 29 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. Form 990, Part III, Line 4b Translational research is a scientific approach that allows reserch observations made in the basic research lab to be quickly tested in the clinic with patients, and results brought back to the lab again in an expedient and systematic way. This research is translating new methods that improve our ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. The research emphasis of the BRI Translational Research Program is in the areas of autoimmune and immune-mediated diseases. BRI scientists and physician collaborators work together to study blood and serum samples along with medial and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy and asthma. BRI maintains an extensive biorepository with samples dating back to 2000, including eight disease categories and a biorepository of healthy people for comparison purposes. Advancements in 2017 include the following 1 Gene Editing Work Continues - BRI and Seattle Childrens Research Institute SCRI are collaborating on a preclinical study pioneering the use of gene editing techniques in efforts to control type 1 diabetes. By isolating the cells that attack the pancreas in type 1 diabetes and reprograming them by editing their genes, there is the hope that this could provide an important step forward in efforts to cure type 1 diabetes and possibly other diseases. To attack this complex problem, BRI is combing its regulatory T cell expertise with SCRIs gene editing expertise. 2 Study Launched to Understand Immune Cell Malfunction - BRI received a grant to help explain why immune cells cause type 1 diabetes, multiple sclerosis, rheumatoid arthritis and many other autoimmune diseases. This will enable BRI researchers to investigate a key mystery Do excess amounts of a chemical called interleukin-6 IL-6 - or an exaggerated response to it - cause T cells to mistake the bodys cells as enemies and attack them Using T cells in blood samples donated to BRIs biorepositories, scientists will try to pinpoint why some T-cells have more IL-6 receptors than others. The researchers will also examine how excess IL-6 changes how T cells function in healthy people and in people with type 1 diabetes, multiple sclerosis and rheumatoid arthritis. 3 Discovery of How Gene Variation Drives Autoimmune Disease - BRI researchers, in collaboration with three other institutions, helped discover that a variation in the gene IFIH1 simultaneously increases the risk of autoimmune disease and helps protect against viruses. The team used model systems and blood cells donated by healthy people to study the IFIH1 variation linked with autoimmunity. The researchers found that the IFIH1 variation enhances how the immune system responds to certain viruses, making it more likely the body will defeat them. But this protection comes with a price the immune system is more likely to mistake the bodys own cells as foreign invaders. This kicks off autoimmune attacks that are the hallmarks of type 1 diabetes, lupus and other autoimmune diseases. 4 Preventing Rheumatoid Arthritis - In the study called TIP-RA Targeting Immune Responses for the Prevention of Rheumatoid Arthritis BRI scientists, in collaboration with three other academic institutions, are looking for ways to prevent rheumatoid arthritis RA from occurring in people with a high risk of the disease. By using single cell analysis, researchers now have the capacity to take a small amount of human blood and look in-depth at specific T cells targeting the joints in RA, to understand what makes them become harmful and attack the body. Once scientists understand what starts RA, then approaches can be developed to stop the disease before it takes hold. Form 990, Part III, Line 4c BRI is dedicated to seeking ways to eliminate type 1 diabetes, while at the same time looking for therapies to prevent, reverse and intervene in the disease at all stages. BRI is an international leader in type 1 diabetes research and has investigated it for more than 30 years, starting with identification of a genetic marker for the disease. BRI continues to lead the Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment. BRI also serves as the TrialNet Hub that includes 23 clinical centers working in cooperation with more than 200 screening and clinical research sites throughout the U.S. and six other countries. Progress in 2017 includes 1 Insulin Pill Study Results TrialNet led the largest study using oral insulin, testing the effect of insulin pills on 560 children and adults whose relatives had type 1 diabetes. For most, the drug had no effect on whether or not they developed type 1 diabetes or how quickly they developed it. But for those at the highest risk of developing the disease, sooner rather than later, insulin pill therapy delayed the time it took to develop the full-blown disease by about two-and-a-half years. 2 Discovery of Unique T cells - BRI researchers recently discovered that patients with type 1 diabetes have a unique set of T cells that have grown and multiplied, increasing the number of bad cells that can attack the pancreas. These unique T cells are rare in healthy individuals, but they exist in significantly higher numbers in patients with type 1 diabetes. Thanks to past technology breakthroughs made at BRI, scientists can find and capture the rare destructive T cells from the thousands of other cells in a drop of blood. Combining this method for capturing the T cells with new technology called single cell RNA sequencing, these cells can now be studied - one cell at a time - in extraordinary detail. This information is then used to decode the bad cells and find out what makes them tick. Form 990, Part III, Line 4d 1 Clinical Research Program Benaroya Research Institute oversees all clinical research at Virginia Mason Medical Center which uniquely combines the expertise of a world-renowned medical reserach institute with the remarkable care of a healthcare quality leader. The BRI Clinical Research Program supports Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. Each year the Clinical Research Program staff annually enrolls approximately 1500 study participants into Virginia Mason trials. This program involves approximately 150 research investigators, oversees 460 active studies and has 110 studies currently open to enrollment. 2 Immunology Research Program Groundbreaking allergy finding - In collaboration with Virginia Mason physicians and their patients blood samples donated to the biorepository combined with tools and techniques of single cell analysis, a groundbreaking allergy discovery was made, altering the course of allergy research. The cell that appears to drive all allergies was identified and named TH2A, providing a promising target for improving diagnosis, monitoring and treatment of all allergies. These cells could be used as biomarkers, or indicators, that show whether a person has an allergy or is responding to allergy therapy. The hope is to at some point be able to identify a signature from a drop of blood that will predict the presence of an allergy long before the first symptoms are experienced. New Clues to Autoimmune Skin Diseases - A team of scientists recently identified a new population of immune cells in the blood that closely resembles immune cells in the skin. They accomplished this by using BRIs combination of expertise, cutting-edge techniques and the latest equipment. While researchers currently know how to isolate immune cells from the blood, immune cells in tissue are difficult to isolate and study, therefore their functions are still poorly understood. Identification of cells in the blood that are related to these immune cells would help scientists better define their functions in health and in disease. This discovery led to a surprising finding these cells may play a vital role not only in protecting us from infection, but also in helping repair damaged tissue. This raises the possibility, and hope, that science can harness these cells for treatment of chronic wounds and autoimmune skin diseases such as scleroderma, psoriasis and atopic dermatitis. New System Model of Multiple Sclerosis Developed - Developed by a BRI researcher, this new system model of multiple sclerosis MS articulates more fully the many complexities of this disease. Scientists can see how the disease progresses and look for better therapies and ways to prevent onset. The model includes several groundbreaking features and studies a factor, the STAT1 gene, shown to have an important role in MS. The new system model is unique because it allows researchers to see what is happening in the central nervous system - the brain and the spinal cord - as well as the immune system, in real time. What is done with system models can potentially lead to new translational and clinical studies that impact disease diagnosis and therapies. Lupus Research Moves Forward - BRI researchers are making important progress in their understanding of what causes lupus through discovery of a novel protein that controls the production of type 1 interferon that could be a target for therapies. Additionally, discovery of a new molecular pathway in lupus that doesnt function properly when people develop lupus is being studied using blood samples of people with and without lupus from the biorepository. Using tetramers, a lab is further investigating the role of T cells in development of lupus. 3 Systems Immunology Division The Systems Immunology Division expanded its scope and resources so as to make single cell analysis available to all areas of the institute. Systems Immunology staff includes PhD computational biologists and biostatisticians with access to a high-performance computing infrastructure and specialized software. By profiling cells at the single cell level, researchers can determine how they are related to each other and how they are related to disease processes. By using sophisticated technologies and data analytics, its possible to read and interpret the molecular blueprints driving cell function, showing the immune system differences that occur during health, disease or during therapy. And with each discovery of important pathways or cells, scientists can then build model systems to confirm whether or not the discovery plays a critical role in immunity. These pathways or cells can then be targets for therapies to eliminate diseases and bring the immune system into balance again. Form 990, Part VI, Section A, Line 1a The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The President and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all of the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. Form 990, Part VI, Section A, Line 6,7 Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. Form 990, Part VI, Section B, Line 11b The VMHS Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provide the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final draft Form 990 is reviewed and approved by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. Form 990, Part VI, Section B, Line 12c The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. Form 990, Part VI, Section B, Line 15 The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee of BRI Executives consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2017 were the Board Director, Carla Greenbaum, the former BRI Director, Gerald Nepom the BRI President and the Executive Director and Chief Financial Officer. Form 990, Part VI, Section C, Line 19 The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. Virginia Mason Health System (VMHS) 1100 Ninth Avenue Seattle WA 98101 911351110 Fundraising WA Sec 501c3 7 NA true Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 Health Care WA Sec 501c3 3 VMHS false Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763656 Education/Research WA Sec 501c3 9 VMMC false Yakima Valley Memorial Hospital Association 2811 Tieton Drive Yakima WA 98902 910567263 Health Care WA Sec 501c3 3 VMHS false false false true false false false false false false true true false false true false true true false false Benaroya Research Institute at Virginia Mason 1201 Ninth Avenue Seattle WA 98101 910653422 0 0 0 71612353 71612353 45128 11282 0 0 0 Virginia Mason Health System 1100 Ninth Avenue Seattle WA 98101 911351110 0 0 0 12576341 12576341 7925 1981 0 0 0 Virginia Mason Medical Center 1100 Ninth Avenue Seattle WA 98101 910565539 X 133386 48767 182153 1029259580 1029441733 648719 162180 0 0 0 Virginia Mason Institute 1100 Ninth Avenue Seattle WA 98101 263763856 0 0 0 7028082 7028082 4429 1107 0 0 0 Yakima Valley Memorial Hospital Association 2811 Tieton Drive Seattle WA 98902 910567263 42094 60000 102094 466123588 466225682 293799 73450 0 0 0